Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Nav

General Info

Geography

Australia (AUS)

Belgium (BEL)

Bulgaria (BGR)

Croatia (HRV)

Czechoslovakia (Czechia, Slovakia)

Czech Republic

Denmark (DNK)

Estonia (EST)

Finland (FIN)

France (FRA)

Germany (DEU)

Greece (GRC)

Hungary (HUN)

Italy (ITA)

Latvia (LVA)

Lithuania (LTU)

Netherlands (NLD)

New Zealand (NZL)

Poland (POL)

Romania (ROU)

Slovakia (SVK)

Spain (ESP)

Sweden (SWE)

Ukraine (UKR)

United Kingdom (GBR)

View all

Time period covered

01/2001 - 12/2008

Data type

Scientific literature

Keywords

Diabetes, Ischemic heart disease, Stroke

Citation

Authors

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Team

Journal

Lancet

Volume

373

Issue

9681

Pages

2125-35

Publication year

2009

Suggested citation

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373(9681): 2125-35.

DOI

10.1016/S0140-6736(09)60953-3

PMID

19501900

GHDx Entry last modified on: Oct 7, 2024

Header sites

Search form

Main menu

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Nav